Company Overview and News

STAG / STAG Industrial, Inc. DEFA14A


7 Stocks to Buy for Big May Dividend Hikes

2018-04-20 investorplace
While most income investors are reaching for big yields right now, a small group of “hidden yield” stocks are quietly handing smart investors growing income streams plus annual returns of 12%, 27.1% and even 54% or more per year.
Upvote Downvote

10 Dividend-Payers to Own for Month-to-Month Income

2018-04-19 investorplace
It’s not complicated. If you’re an investor seeking steady, reliable income on your capital, the market offers a huge number of dividend-paying stocks.
Upvote Downvote

Baird REIT Dividend Portfolio Offers Safety and Huge Payouts

2018-04-19 247wallst
Even though interest rates have gone up, and the expectations are for more increases this year and next, on a historical basis rates remain near generational lows. That’s very hard on investors that look to dividends and interest income to live on or to supplement retirement funds. Sure there are double-digit yields out there, but the securities and funds that offer those yields bring investors a commiserate amount of risk.
Upvote Downvote

STAG / STAG Industrial, Inc. 8-K (Current Report)

Upvote Downvote

The More It Drops, The More I Buy - Part 2

2018-04-11 seekingalpha
After the latest market correction, REITs are priced at historically cheap valuations based on P/NAV, P/FFO, and Yield Spreads.
Upvote Downvote

Don't Follow The Herd, Buy STAG

2018-04-09 seekingalpha
Always remembering that if people in masses are buying, then there must be someone who is selling.
Upvote Downvote

If I Had To Build An Income Portfolio Today - Update 28

2018-04-09 seekingalpha
This article is Update 28 to my original article entitled "If I Had to Build An Income Portfolio Today."
Upvote Downvote

Consider Equity REITs For Your Next Investment: STAG Industrial

2018-04-05 valuewalk
I recently wrote an article for Sure Dividend entitled “Consider Equity REITs for Your Next Investment“. In that article, I listed nine equity REITs (eREITs) for dividend investors to consider in light of the drubbing that eREIT valuations have recently taken due to fear of rising interest rates and to capitalize on the pass-through provision for REIT income included in the new tax legislation. Both of these topics are covered in some detail in the previous article.
Upvote Downvote

Our High Yield, Value REIT Portfolio Designed For Outperformance

2018-04-05 seekingalpha
The ~9.22% yield is fully supported with a lower FFO payout ratio than the average REIT.
Upvote Downvote

Consider Equity REITs For Your Next Investment

2018-04-04 valuewalk
Real Estate Investment Trusts (REITs) that invest primarily in equity (land, buildings, and equipment) have been solid long term investments for several decades. While there are always a few bad apples in the barrel and economic conditions sometimes conspire against investors, equity REITs (eREITs) have generally provided investors with steady long term returns.
Upvote Downvote

The More It Drops, The More I Buy

2018-04-02 seekingalpha
The REIT market continues to sell off – hitting new lows almost on a weekly basis.
Upvote Downvote

Don't Put All Your Eggs In One Basket

2018-03-31 seekingalpha
Diversification strives to smooth out risk in a portfolio so the positive performance of some investments neutralizes the negative performance of others.
Upvote Downvote

REITs That Albert Einstein Would Likely Buy

2018-03-28 seekingalpha
For anyone who wants to build lasting wealth, understanding and harnessing the power of compound interest is vital.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 85254J102